As an important alternative to the original drug, the abemaciclib generic (BESIDX) produced by Lao Big Bear Pharmaceutical has entered the market at a···【Read More】
Update: 2026-06-25Source: Haiou HealthViews: 151
Abemaciclib, marketed under the brand name BESIDX by Bigbear Pharma in Laos, is a CDK4/6 selective inhibitor indicated for hormone receptor (HR)-posit···【Read More】
Update: 2026-06-25Source: Haiou HealthViews: 167
As a legitimate generic version of Lorlatinib officially approved for marketing by the Lao Ministry of Health, LORLADX (100mg×30 tablets/box) manufact···【Read More】
Update: 2026-06-25Source: Haiou HealthViews: 161
Against the backdrop of prohibitively high targeted drug costs that deter many patients, the lorlatinib generic (trade name LORLADX) launched by Lao B···【Read More】
Update: 2026-06-25Source: Haiou HealthViews: 174
Lorlatinib (formerly known as lorlatinib), as a third-generation dual-target small-molecule inhibitor of ALK and ROS1, exhibits potent inhibitory effe···【Read More】
Update: 2026-06-25Source: Haiou HealthViews: 184
As the generic version of Lusutrombopag launched by Big Bear Pharmaceutical in Laos, LUTRODX provides a new treatment option for adult patients with c···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 153
Lusutrombopag is an oral small-molecule thrombopoietin receptor agonist (TPO-RA) that promotes platelet production by activating the thrombopoietin re···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 150
BigBear Pharma (BIGBEARPharma) in Laos announced that its generic version of Lusutrombopag, LUTRODX, has received marketing authorization from the Lao···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 157
Binimetinib, as an ATP-noncompetitive reversible MEK1/2 inhibitor, plays an important role in the treatment of unresectable or metastatic melanoma wit···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 143
For many oncology patients facing prohibitively high targeted therapy costs, the Lao Dabang version of Binimetinib undoubtedly brings new hope—this ge···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 140
BigBearPharma (Laos) has announced that its generic version of Binimetinib has officially received approval from the Lao Ministry of Health, under the···【Read More】
Update: 2026-06-24Source: Haiou HealthViews: 139
Based on the durable efficacy and intracranial activity demonstrated in the TRIDENT-1 clinical trial, the next-generation ROS1/TRK inhibitor repotrect···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 143
When the original drug Repotrectinib, with a monthly treatment cost of tens of thousands of dollars, puts it out of reach for many patients, the gener···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 122
Repotrectinib, as a next-generation ROS1 and NTRK targeted inhibitor, can effectively overcome multiple resistance mutations to other tyrosine kinase ···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 156
Cabozantinib, known as the "troublemaker" among targeted therapies, can simultaneously inhibit multiple key targets including VEGFR, C-MET, ···【Read More】
Update: 2026-06-23Source: Haiou HealthViews: 157
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos